Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Daniele, Simona ^a   Giacomelli, Chiara ^a   Zappelli, Elisa ^a   Granchi, Carlotta ^a   Trincavelli, Maria Letizia ^a   Minutolo, Filippo ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN TUMOR; CELL DIFFERENTIATION; ENZYMOLOGY; GLIOBLASTOMA; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MEMBRANE POTENTIAL, MITOCHONDRIAL;

EID: 84945157375     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15556     Document Type: Article

References (55)

1. Stupp, R., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncol. 10, 459-466 (2009).
2. Bao, S., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
3. Frank, N. Y., Schatton, T. & Frank, M. H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 120, 41-50 (2010).
4. Liu, G., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer. 5, 67 (2006).
5. Zhao, Y., Butler, E. B. & Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell. Death. Dis. 4, e532 (2013).
6. Galluzzi, L., Kepp, O., Vander Heiden, M. G. & Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug. Discov. 12, 829-846 (2013).
7. Menendez, J. A., et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell. Cycle 12, 1166-1179 (2013).
8. Pecqueur, C., Oliver, L., Oizel, K., Lalier, L. & Vallette, F. M. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int. J. Cell. Biol. 2013, 805975 (2013).
9. Zhou, Y., et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J. Biol. Chem. 286, 32843-32853 (2011).
10. Yuan, S., et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem. Cells. 31, 23-34 (2013).
11. Granchi, C. & Minutolo, F. Anticancer agents that counteract tumor glycolysis. Chem Med Chem. 7, 1318-1350 (2012).
12. Granchi, C., Fancelli, D. & Minutolo, F. An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg. Med. Chem. Lett. 24, 4915-4925 (2014).
13. Michelakis, E. D., et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2, 31-34 (2010).
14. Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685-3692 (2013).
15. Granchi, C., Paterni, I., Rani, R. & Minutolo, F. Small-molecule inhibitors of human LDH5. Future. Med. Chem. 5, 1967-1991 (2013).
16. Crane, C. A., et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc. Natl. Acad. Sci. USA 111, 12823-12828 (2014).
17. Koukourakis, M. I., Giatromanolaki, A., Simopoulos, C., Polychronidis, A. & Sivridis, E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin. Exp. Metastasis. 22, 25-30 (2005).
18. Kim, J., et al. High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma. Int. J. Oncol. 47, 1009-1016 (2015).
19. Koukourakis, M. I., et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin. Cancer. Res. 17, 4892-4900 (2011).
20. Koukourakis, M. I., et al. Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer. Sci. 97, 1056-1060 (2006).
21. Xie, H., et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer. Ther. 8, 626-635 (2009).
22. Le, A., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 107, 2037-2042 (2010).
23. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer. Cell. 9, 425-434 (2006).
24. Wolf, A., Agnihotri, S. & Guha, A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 1, 552-562 (2010).
25. Xie, H., et al. Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell. Metab. 19, 795-809 (2014).
26. Granchi, C., et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J. Med. Chem. 54, 1599-1612 (2011).
27. Granchi, C., et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2- carboxylate (NHI) and malonic (Mal) scaffolds. Org. Biomol. Chem. 11, 6588-6596 (2013).
28. Granchi, C., et al. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Eur. J. Med. Chem. 46, 5398-5407 (2011).
29. Calvaresi, E. C., et al. Dual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. Chembiochem. 14, 2263-2267 (2013).
30. Allison, S. J., et al. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. Oncogenesis 3, e102 (2014).
31. Maftouh, M., et al. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br. J. Cancer. 110, 172-182 (2014).
32. Stacpoole, P. W., Nagaraja, N. V. & Hutson, A. D. Efficacy of dichloroacetate as a lactate-lowering drug. J. Clin. Pharmacol. 43, 683-691 (2003).
33. Ishii, N., et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9, 469-479 (1999).
34. Notarangelo, A., et al. Establishment and genetic characterization of ANGM-CSS, a novel, immortal cell line derived from a human glioblastoma multiforme. Int. J. Oncol. 44, 717-724 (2014).
35. Wang, C. C., et al. HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res. 66, 6756-6762 (2006).
36. Ciavardelli, D., et al. Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell. Death. Dis. 5, e1336 (2014).
37. Daniele, S., Zappelli, E., Natali, L., Martini, C. & Trincavelli, M. L. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell. Death. Dis. 5, e1539 (2014).
38. Piccirillo, S. G., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 444, 761-765 (2006).
39. Morfouace, M., et al. Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J. Biol. Chem. 287, 33664-33674 (2012).
40. Vander Heiden, M. G., et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499 (2010).
41. Christofk, H. R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
42. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
43. Maldonado, E. N. & Lemasters J. J. ATP/ADP ratio, the missed connection between mitochondria and the Warburg effect. Mitochondrion. 19, 78-84 (2014).
44. Yuan, S., et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells. 31, 23-34 (2013).
45. Li, Z., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer. Cell. 15, 501-513 (2009).
46. Soeda, A., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28, 3949-3959 (2009).
47. Oudard, S., et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br. J. Cancer 74, 839-845 (1996).
48. Maher, J. C., Krishan, A. & Lampidis, T. J. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother. Pharmacol. 53, 116-122 (2004).
49. Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene. 25, 4633-4646 (2006).
50. Mendez, O., et al. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol. Cancer 9, 133 (2010).
51. Bar, E. E., Lin, A., Mahairaki, V., Matsui, W. & Eberhart, C. G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 177, 1491-1502 (2010).
52. Lu, H., et al. The differentiation of skeletal muscle cells involves a protein-tyrosine phosphatase-alpha-mediated C-Src signaling pathway. J. Biol. Chem. 277, 46687-46695 (2002).
53. Costa, B., et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One 8, e72281 (2013).
54. Daniele, S., et al. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci. Rep. 4, 4749 (2014).
55. Fernando, P., Brunette, S. & Megeney, L. A. Neural stem cell differentiation is dependent upon endogenous caspase 3 activity. FASEB J. 19, 1671-1673 (2005).